Inactief instrument

Andere talen QSAM Biosciences, Inc. Other OTC

Aandelen

QSAM

US74738N1037

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others.	03/05
QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER	16/04
QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals	07/02
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee	14/11
Telix Pharmaceuticals Limited signed a non-binding term sheet to acquire QSAM Biosciences, Inc. for $33.1 million.	14/11
QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
QSAM Biosciences, Inc. announced that it has received $0.600001 million in funding	29-09-23
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data	16-08-23
QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14-08-23
QSAM BIOSCIENCES, INC. : Unregistered Sale of Equity Securities (form 8-K)	23-06-23
QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®	14-06-23
QSAM Biosciences, Inc. Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®	14-06-23
QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center	23-05-23
QSAM Biosciences Expands Its Study of Cyclosam(R) in the Treatment of Bone Cancer; Opens Patient Enrollment At Key Chicago Center, Insight Hospital and Medical Center	23-05-23
QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®	16-05-23
QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15-05-23
QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®	26-04-23
QSAM Biosciences, Inc. Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam	26-04-23
QSAM BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	11-04-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen QSAM Biosciences, Inc. Other OTC

Aandelen

QSAM

US74738N1037

Andere talen

Filters